HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Invasive pulmonary aspergillosis — Clinical Guidelines

Overview

Invasive pulmonary aspergillosis (IPA) is a severe fungal infection primarily affecting immunocompromised individuals, characterized by invasive growth of Aspergillus species in lung tissue, leading to significant morbidity and mortality 1.

Diagnosis

Risk Factors: Persistent neutropenia, allogeneic stem cell transplantation, congenital or acquired immunodeficiency, decompensated liver cirrhosis, COPD, solid tumors, and viral pneumonia (e.g., influenza, COVID-19) 1.

Diagnostic Tests: Galactomannan (GM) test in bronchoalveolar lavage (BAL), bronchial lavage (BL), and serum; (1,3)-β-D-glucan test; PCR 3.

Performance Metrics: BAL GM shows moderate to high diagnostic accuracy (AUC 0.731); BL GM has the best diagnostic value (AUC 0.869) 2.

Impact of Prophylaxis: Posaconazole prophylaxis may reduce sensitivity of GM measurements without affecting specificity 2.

Management

First-Line Treatment: Voriconazole is typically recommended as first-line therapy 1.

Adjunctive Measures: Surgical debridement in cases of localized disease or complications 1.

Prophylaxis: Posaconazole prophylaxis is considered in high-risk patients to reduce incidence 2.

Special Populations

Renal Impairment: Specific dosing adjustments may be necessary for antifungal agents in patients with renal impairment, though detailed dosing recommendations are not provided in the abstracts 1.

Environmental Factors: Increased risk during hospital renovations; environmental controls like HEPA filtration and laminar airflow can mitigate risk 4 5 6.

Key Recommendations

Consider IPA in Critically Ill Patients with Persistent Respiratory Deterioration, especially those with recognized risk factors (Evidence: Strong 1).

Utilize Galactomannan Testing in BAL and BL for IPA Diagnosis, with BL showing superior diagnostic performance (Evidence: Moderate 2).

Implement Environmental Controls During Hospital Renovations to reduce Aspergillus exposure in immunocompromised patients (Evidence: Moderate 4 5 6).

References

1 Wichmann D, Hoenigl M, Koehler P, Koenig C, Lund F, Mang S et al.. Diagnosis and treatment of invasive pulmonary aspergillosis in critically ill intensive care patients: executive summary of the German national guideline (AWMF 113-005). Infection 2025. link 2 Acet-Öztürk NA, Ömer-Topçu D, Vurat Acar K, Aydın-Güçlü Ö, Pınar İE, Demirdöğen E et al.. Impact of posaconazole prophylaxis and antifungal treatment on BAL GM performance in hematology malignancy patients with febrile neutropenia: a real life experience. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2024. link 3 Liu M, Cheng G, Xiong C, Xiao W, Du LY, Mao B et al.. Diagnostic performance of mycological tests for invasive pulmonary aspergillosis in non-haematological patients: protocol for a systematic review and meta-analysis. BMJ open 2022. link 4 Pini G, Faggi E, Donato R, Sacco C, Fanci R. Invasive pulmonary aspergillosis in neutropenic patients and the influence of hospital renovation. Mycoses 2008. link 5 Berthelot P, Loulergue P, Raberin H, Turco M, Mounier C, Tran Manh Sung R et al.. Efficacy of environmental measures to decrease the risk of hospital-acquired aspergillosis in patients hospitalised in haematology wards. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006. link 6 Cornet M, Levy V, Fleury L, Lortholary J, Barquins S, Coureul MH et al.. Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infection control and hospital epidemiology 1999. link

Invasive pulmonary aspergillosis